IMRA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (24 Feb 2023 @ 05:00):

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin...

Stats
今日成交量	271 721
平均成交量	116 259
市值	165.80M
EPS	$-0.000510 ( 2023-09-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	105.33
ATR14	$0.322 (5.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-29	Lyssikatos Joseph P	Sell	12 000	Stock Option (right to buy)
2023-12-29	Lyssikatos Joseph P	Buy	12 000	Common Stock
2023-12-29	Lyssikatos Joseph P	Sell	9 151	Common Stock
2023-12-29	Lyssikatos Joseph P	Sell	2 849	Common Stock
2023-12-28	Patel Anish	Sell	2 520	Common Stock

INSIDER POWER
82.98
Last 97 transactions
Buy: 15 631 291 \| Sell: 878 871

音量相关性

長: -0.10 (neutral)

短: 0.82 (strong)

Signal:(75.335) Same movement expected

Imara Inc 相关性

10 最正相关
BOCH	0.938
MMAC	0.916
SHSP	0.895
LMST	0.886
NETE	0.885
MNSB	0.859
SMCI	0.857
VOXX	0.844
WSC	0.841
STRL	0.84

10 最负相关
RMRM	-0.956
TDAC	-0.93
APOP	-0.923
GAINL	-0.91
AEY	-0.888
UK	-0.878
SVOK	-0.873
FANG	-0.865
BNRG	-0.862
HUSN	-0.861

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Imara Inc 相关性 - 货币/商品

0.46
( neutral )

0.66
( moderate )

-0.51
( weak negative )

0.67
( moderate )

-0.53
( weak negative )

Imara Inc 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0.240

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0.240

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.06

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.53

Financial Reports:

No articles found.

Imara Inc

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.